GlassScriptPhysician profile
Ryan N Richardson
NPI 1346209293
$5,291.72
in general payments reported to CMS, 2019-2025
24 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $232 · 2021: $478 · 2022: $3,958 · 2023: $185 · 2024: $57.26 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $385.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $3,389.99 | 2019-2025 | |
| Abbvie INC. | $320.99 | 2019-2023 | |
| Astellas Pharma US INC | $214.90 | 2021-2023 | Myrbetriq |
| Avion Pharmaceuticals | $178.23 | 2019-2022 | |
| Exeltis, USA INC. | $154.58 | 2021-2023 | Slynd |
| Novo Nordisk INC | $135.08 | 2019-2025 | Wegovy |
| Mylan Pharmaceuticals INC. | $129.10 | 2019-2022 | |
| Therapeuticsmd, INC. | $99.01 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.69 | 2019-2021 | |
| Myovant Sciences INC. | $73.83 | 2021-2022 | |
| Shield Therapeutics INC | $70.34 | 2023-2024 | Accrufer |
| Medtronic, INC. | $64.39 | 2025 | Truclear |
| Boston Scientific Corporation | $54.05 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Bayer Healthcare Pharmaceuticals INC. | $49.07 | 2022 | |
| Currax Pharmaceuticals LLC | $41.91 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $39.84 | 2022 | |
| Organon LLC | $38.21 | 2022-2023 | Nexplanon |
| Mayne Pharma Commercial LLC | $37.58 | 2022-2023 | |
| Scynexis, INC. | $34.20 | 2022 | |
| Sumitomo Pharma America, INC. | $23.63 | 2023 | Myfembree |
| Evoke Pharma, INC. | $19.02 | 2025 | |
| Biogen, INC. | $17.30 | 2025 | Zurzuvae |
| Agile Therapeutics, INC. | $13.65 | 2022 | |
| Merck Sharp & Dohme LLC | $11.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Richardson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.